Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback